It seems we can’t find what you’re looking for. Perhaps searching can help.
Nothing found
Latest Articles
-
Cumberland Pharmaceuticals (NASDAQ: CPIX) Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease
February 5, 2025 Comments Off on Cumberland Pharmaceuticals (NASDAQ: CPIX) Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart DiseaseNASHVILLE, Tenn., Feb. 4, 2025 — Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase 2 FIGHT DMD trial. [...] -
February 5, 2025 Comments Off on Pasithea Therapeutics (NASDAQ: KTTA) Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
-
January 30, 2025 Comments Off on BigBear.ai (NYSE: BBAI)Awarded Prime IDIQ Contract for U.S. Department of Navy’s SeaPort Next Generation (NxG)
-
January 30, 2025 Comments Off on ScanTech AI Systems (NASDAQ: STAI) Deploys Its Advanced AI-Driven Security Screening Technology to Protect Multiple Nuclear Power Plants Operated by Ontario Power Generation
-
January 30, 2025 Comments Off on Kazia Therapeutics (NASDAQ: KZIA) announces launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer
Popular Articles
-
Cumberland Pharmaceuticals (NASDAQ: CPIX) Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease
February 5, 2025 Comments Off on Cumberland Pharmaceuticals (NASDAQ: CPIX) Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart DiseaseNASHVILLE, Tenn., Feb. 4, 2025 — Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase 2 FIGHT DMD trial. [...] -
February 9, 2009 Comments Off on Post 2
-
February 9, 2009 Comments Off on Palm(NASDAQ: PALM) builds momentum;
-
February 9, 2009 Comments Off on Post 4
-
February 10, 2009 Comments Off on Value Investing Opportunities (Prospect List Here)